Crinetics Pharmaceuticals Joins the Healthcare Conference
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), based in San Diego, is gearing up to take part in a key healthcare event that is set to gather industry leaders and innovators. The Jefferies Global Healthcare Conference will be held soon, specifically from June 3-5. This prestigious gathering in New York offers a platform for Crinetics to share its discoveries and outline its future in the healthcare landscape.
Details of Crinetics' Presentation
During the event, Crinetics will showcase its advancements on Thursday, June 5, with a presentation scheduled for 12:50 p.m. Eastern Time. Attendees will have the opportunity to listen to company management discuss their groundbreaking work and future objectives. This presentation is expected to highlight the innovative therapeutic solutions Crinetics is developing for patients with endocrine disorders.
Accessing the Live Webcast
For those interested in following Crinetics' participation, a live and archived webcast will be accessible on the company's official Events & Presentations page. This allows investors and stakeholders to engage with the conference from wherever they are. The webcast can be accessed directly from the Crinetics website.
Engagement Opportunities
In addition to the presentation, interested parties have the chance to arrange one-on-one meetings with Crinetics management. If you're keen on a direct discussion regarding the company's initiatives, it's recommended to reach out to your conference representative to explore this networking opportunity.
Industrial Overview of Crinetics Pharmaceuticals
Crinetics is positioned as a clinical-stage pharmaceutical entity that aims to innovate and advance therapies focused on endocrine diseases and related tumors. Crinetics is making significant strides with its leading candidate, paltusotine, recognized as the first oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist currently in clinical development. This treatment is designed specifically for patients experiencing acromegaly and carcinoid syndrome tied to neuroendocrine tumors.
Expanding the Product Pipeline
In addition to paltusotine, Crinetics is working on Atumelnant, intended for treating congenital adrenal hyperplasia and conditions like ACTH-dependent Cushing’s syndrome. All of their pipeline medications are small molecules, delivered orally, showcasing innovation born from their extensive in-house discovery processes. Moreover, the company is actively seeking solutions for various endocrine-related issues, from hyperparathyroidism to polycystic kidney disease and diabetes.
Investor and Media Relations Contact
Crinetics emphasizes communication with stakeholders through their dedicated investor relations team. For inquiries, Gayathri Diwakar, the Head of Investor Relations, can be reached at gdiwakar@crinetics.com or through her direct line at (858) 345-6340. Additionally, Natalie Badillo manages corporate communications and can be contacted at nbadillo@crinetics.com for media-related questions at (858) 345-6075.
Frequently Asked Questions
What is the Jefferies Global Healthcare Conference?
The Jefferies Global Healthcare Conference is a significant event where companies present their latest healthcare innovations and engage with investors.
When is Crinetics Pharmaceuticals' presentation scheduled?
Crinetics will present on June 5, 2025, at 12:50 p.m. Eastern Time.
How can investors access the event presentation?
Investors can watch the live and archived presentation on the Crinetics Events & Presentations page on their website.
What are the key products being developed by Crinetics Pharmaceuticals?
The key products include paltusotine for acromegaly and carcinoid syndrome, and Atumelnant for congenital adrenal hyperplasia.
Who can be contacted for investor inquiries?
For investor inquiries, reach out to Gayathri Diwakar at gdiwakar@crinetics.com.
